

REMARKS

Prior to the present amendment, Claims 1-4, 6, 13 and 14 were pending in the application. By this amendment, Claim 6 is cancelled. Claim 1 was amended, deleting the terms "prodrug" and "hydrate", as well as the period at the end of line 8. Claim 4 was amended, deleting the words "acid" and "ester" from line 22. Applicants reserve the right to file a continuation or divisional application to subject matter not claimed herein.

Applicants added new Claim 16 – a method of treatment claim. Basis for the claim may be found in cancelled Claim 15. The indications are limited, however, to scleroderma and dermal scarring.

No new matter has been added by the amendments herein.

Objection to Claims 1, 4 and 6

In the interest of furthering prosecution, Applicants amended the claims – without prejudice – as suggested by the Examiner. The above amendments overcome the objections.

35 U.S.C. § 112 (2nd Par.) Rejection of Claims 4 and 6

Claim 4 was amended, deleting the words "acid" and "ester" from line 22. Claim 6 was cancelled. Applicants reserve the right to file any cancelled subject matter herein in other applications. The above amendments obviate the basis for the rejection of Claim 4.

35 U.S.C. § 112 (1st Par.) Rejection of Claims 1-4 and 6, 13 and 14

Claim 1 was amended, deleting the terms "prodrugs" and "hydrates." Claim 6 was cancelled. Accordingly, the above amendments have overcome the rejection of those remaining claims. Applicants reserve the right to file any cancelled subject matter herein in other applications.

CONCLUSION

Having addressed all points and concerns raised by the Examiner, Applicants respectfully submit that the application is in condition for allowance and request an early and favorable action in this application.

Respectfully submitted,

Date: September 25, 2007
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4288

/ Martha G. Munchhof /
Martha G. Munchhof
Attorney for Applicant(s)
Reg. No. 47,811